Aromatase inhibitors in men: Effects and therapeutic options

Reproductive Biology and Endocrinology

Volumn 9, Issue , 2011, Pages

  de Ronde, Willem ^a   de Jong, Frank H ^b  

^a Kennemer Gasthuis ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; GONADOTROPIN; LETROZOLE; LUTEINIZING HORMONE; TESTOSTERONE;

BODY HEIGHT; BREAST CARCINOMA; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; EPIPHYSIS; ESTROGEN METABOLISM; IDIOPATHIC DISEASE; OBESITY; PATIENT SAFETY; PHENOTYPE; PRECOCIOUS PUBERTY; REVIEW; SEX DIFFERENCE; SHORT STATURE; SPERMATOGENESIS; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; ADOLESCENT; BONE DEVELOPMENT; BREAST; CHILD; DRUG EFFECT; GROWTH DISORDER; HUMAN; MALE; PUBERTY;

ADOLESCENT; AROMATASE INHIBITORS; BODY HEIGHT; BONE DEVELOPMENT; BREAST; CHILD; GROWTH DISORDERS; HUMANS; MALE; OBESITY; PUBERTY; PUBERTY, PRECOCIOUS; SPERMATOGENESIS; TESTOSTERONE;

EID: 79959245842     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-9-93     Document Type: Review

References (88)

1. Jones ME, Boon WC, McInnes K, Maffei L, Carani C, Simpson ER. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab 2007, 3:414-421.
2. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635. 10.1200/JCO.2005.05.4882, 16822845.
3. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005, 23:5126-5137. 10.1200/JCO.2005.07.097, 15983390.
4. de Ronde W. Therapeutic uses of aromatase inhibitors in men. Curr Opin Endocrinol Diabetes Obes 2007, 14:235-240. 10.1097/MED.0b013e328121aad2, 17940445.
5. Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 2001, 142:4589-4594. 10.1210/en.142.11.4589, 11606422.
6. Stoffel-Wagner B, Watzka M, Schramm J, Bidlingmaier F, Klingmüller D. Expression of CYP19 (aromatase) mRNA in different areas of the human brain. J Steroid Biochem Mol Biol 1999, 70:237-241. 10.1016/S0960-0760(99)00114-4, 10622413.
7. Schindler AE, Ebert A, Friedrich E. Conversion of androstenedione to estrone by human tissue. J Clin Endocrinol Metab 1972, 35:627-630. 10.1210/jcem-35-4-627, 5052980.
8. Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab 1994, 78:428-432. 10.1210/jc.78.2.428, 8106632.
9. Longcope C, Pratt JH, Schneider SH, Fineberg SE. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 1978, 46:146-152. 10.1210/jcem-46-1-146, 752017.
10. Schweikert HU, Milewich L, Wilson JD. Aromatization of androstenedione by isolated human hairs. J Clin Endocrinol Metab 1975, 40:413-417. 10.1210/jcem-40-3-413, 1117053.
11. Schweikert HU, Wolf L, Romalo G. Oestrogen formation from androstenedione in human bone. Clin Endocrinol (Oxf) 1995, 43:37-42.
12. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y. Localized expression of aromatase in human vascular tissues. Circ Res 1999, 84:1285-1291.
13. Baird DT, Horton R, Longcope C, Tait JF. Steroid dynamics under steady-state conditions. Recent Prog Horm Res 1969, 25:611-664.
14. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979, 49:905-916. 10.1210/jcem-49-6-905, 511978.
15. de Ronde W, Hofman A, Pols HA, de Jong FH. A direct approach to the estimation of the origin of oestrogens and androgens in elderly men by comparison with hormone levels in postmenopausal women. Eur J Endocrinol 2005, 152:261-268. 10.1530/eje.1.01830, 15745935.
16. de Ronde W, van der Schouw YT, Muller M, Grobbee DE, Gooren LJ, Pols HA, de Jong FH. Associations of sex hormone binding globulin (SHBG) with non-SHBG-bound levels of testosterone and estradiol in independently living men. J Clin Endocrinol Metab 2005, 90:157-162.
17. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997, 337:91-95. 10.1056/NEJM199707103370204, 9211678.
18. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004, 89:61-70. 10.1210/jc.2003-030313, 14715828.
19. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995, 80:3689-3698. 10.1210/jc.80.12.3689, 8530621.
20. Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, Mann K, Broecker M. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 2002, 87:5476-5484. 10.1210/jc.2002-020498, 12466340.
21. Mittre Hervé MH, Kottler M, Pura M. Human gene mutations. Gene symbol: CYP19. Diseaese: aromatase deficiency. Hum Genet 2004, 114:124.
22. Bouillon R, Bex M, Vanderschueren D, Boonen S. Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 2004, 89:6025-6029. 10.1210/jc.2004-0602, 15579754.
23. Lanfranco F, Pignatti E, Corneli G, Ghigo E, Aimaretti G, Carani C, Rochira V. A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. Bone 2008, 43:628-635. 10.1016/j.bone.2008.05.011, 18590994.
24. Deladoëy J, Flück C, Bex M, Yoshimura N, Harada N, Mullis PE. Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab 1999, 84:4050-4054. 10.1210/jc.84.11.4050, 10566648.
25. Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q, Yue W, Mitsiades CS, Flor AW, Chrousos GP. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998, 83:1348-1357. 10.1210/jc.83.4.1348, 9543166.
26. Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Bulun SE. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003, 348:1855-1865. 10.1056/NEJMoa021559, 12736278.
27. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
28. Raven G, de Jong FH, Kaufman JM, de Ronde W. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 2006, 91:3324-3328. 10.1210/jc.2006-0462, 16787981.
29. T'sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM. Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 2005, 90:5717-5722. 10.1210/jc.2005-0982, 16046582.
30. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000, 106:1553-1560. 10.1172/JCI10942, 381474, 11120762.
31. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20:751-757. 10.1200/JCO.20.3.751, 11821457.
32. Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF, Hayes FJ. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 2008, 93:784-791. 2266963, 18073301.
33. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26:833-876. 10.1210/er.2004-0013, 15901667.
34. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91:1995-2010. 10.1210/jc.2005-2847, 16720669.
35. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005, 28:125-127. 10.1111/j.1365-2605.2005.00553.x, 15910536.
36. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004, 89:1174-1180. 10.1210/jc.2003-031467, 15001605.
37. Muller M, van den Beld AW, van der Schouw YT, Grobbee DE, Lamberts SW. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J Clin Endocrinol Metab 2006, 91:3988-3991. 10.1210/jc.2005-2433, 16804050.
38. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2009, 70:116-123.
39. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999, 84:1966-1972. 10.1210/jc.84.6.1966, 10372695.
40. Kley HK, Deselaers T, Peerenboom H, Kruskemper HL. Enhanced conversion of androstenedione to estrogens in obese males. J Clin Endocrinol Metab 1980, 51:1128-1132. 10.1210/jcem-51-5-1128, 7419688.
41. Strain GW, Zumoff B, Miller LK, Rosner W, Levit C, Kalin M, Hershcopf RJ, Rosenfeld RS. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab 1988, 66:1019-1023. 10.1210/jcem-66-5-1019, 3129444.
42. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 2005, 7:211-215. 10.1111/j.1463-1326.2004.00397.x, 15811136.
43. Zumoff B, Miller LK, Strain GW. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003, 52:1126-1128. 10.1016/S0026-0495(03)00186-0, 14506617.
44. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008, 158:741-747. 10.1530/EJE-07-0663, 18426834.
45. Cohen PG. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008, 70:358-360. 10.1016/j.mehy.2007.05.020, 17825496.
46. Roth MY, Amory JK, Page ST. Treatment of male infertility secondary to morbid obesity. Nat Clin Pract Endocrinol Metab 2008, 4:415-419. 10.1038/ncpendmet0844, 2664380, 18523426.
47. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996, 81:1821-1826. 10.1210/jc.81.5.1821, 8626841.
48. Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000, 2:CD000151.
49. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001, 165:837-841. 10.1016/S0022-5347(05)66540-8, 11176482.
50. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002, 167:624-629. 10.1016/S0022-5347(01)69099-2, 11792932.
51. Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril 2011, 95:809-811. 10.1016/j.fertnstert.2010.09.021, 20934689.
52. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a doubleblinded, randomized, placebo-controlled trial with crossover. J Androl 1989, 10:240-247.
53. Cakan M, Aldemir M, Topcuoglu M, Altuǧ U. Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men. Urol Int 2009, 83:446-451. 10.1159/000251186, 19996653.
54. Ramasamy R, Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN. Successful fertility treatment for Klinefelter's syndrome. J Urol 2009, 182:1108-1113. 10.1016/j.juro.2009.05.019, 19616796.
55. Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougnères P, Carel JC. Prepubertal gynecomastia in Peutz- Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol 2006, 154:221-227. 10.1530/eje.1.02085, 16452534.
56. Laue L, Jones J, Barnes KM, Cutler GB. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993, 76:151-155. 10.1210/jc.76.1.151, 8421081.
57. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006, 149:416-420. 10.1016/j.jpeds.2006.04.027, 16939760.
58. Reiter EO, Mauras N, McCormick K, Kulshreshtha B, Amrhein J, De Luca F, O'Brien S, Armstrong J, Melezinkova H. Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 2010, 23:999-1009. 10.1515/jpem.2010.161, 21158211.
59. Lenz AM, Shulman D, Eugster EA, Rahhal S, Fuqua JS, Pescovitz OH, Lewis KA. Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics 2010, 126:e728-e733. 10.1542/peds.2010-0596, 20713483.
60. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005, 90:6396-6402. 10.1210/jc.2005-1392, 16189252.
61. Veldhuis JD, Mielke KL, Cosma M, Soares-Welch C, Paulo R, Miles JM, Bowers CY. Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men. J Clin Endocrinol Metab 2009, 94:973-981. 2681279, 19088159.
62. Hero M, Mäkitie O, Kröger H, Nousiainen E, Toiviainen-Salo S, Dunkel L. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res 2009, 71:290-297. 10.1159/000208803, 19339794.
63. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008, 93:823-831. 2266949, 18165285.
64. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty a randomised controlled trial. Lancet 2001, 357:1743-1748. 10.1016/S0140-6736(00)04895-9, 11403810.
65. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006, 64:510-513.
66. Van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985, 45:2900-2906.
67. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, Diamond FB, Backeljauw PF. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebocontrolled trial. J Clin Endocrinol Metab 2004, 89:4428-4433. 10.1210/jc.2004-0082, 15356042.
68. Maidment SL. Question 2. Which medications effectively reduce pubertal gynaecomastia?. Arch Dis Child 2010, 95:237-9. 10.1136/adc.2009.176768, 20308342.
69. Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005, 23:808-815. 10.1200/JCO.2005.12.013, 15681525.
70. Saltzstein D Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005, 8:75-83. 10.1038/sj.pcan.4500782, 15685254.
71. Hayes TG. Pharmacologic treatment of male breast cancer. Exp Opin Pharmacother 2009, 10:2499-2510.
72. Soon Wong N, Seong Ooi W, Pritchard KI. Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain. J Clin Oncol 2007, 25:3787.
73. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW, Felson DT. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000, 133:951-963.
74. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, Duboeuf F, Delmas PD. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001, 86:192-199. 10.1210/jc.86.1.192, 11232000.
75. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83:2266-2274. 10.1210/jc.83.7.2266, 9661593.
76. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001, 86:3555-3561. 10.1210/jc.86.8.3555, 11502778.
77. Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S, Lucani B, Dal Canto N, Valenti R, Gennari C, Nuti R. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003, 88:5327-5333. 10.1210/jc.2003-030736, 14602769.
78. Khosla S, Melton LJ III, Robb RA, Camp JJ, Atkinson EJ, Oberg AL, Rouleau PA, Riggs BL. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 2005, 20:730-740.
79. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982, 16:801-810. 10.1016/0022-4731(82)90038-3, 7202083.
80. Szulc P, Claustrat B, Munoz F, Marchand F, Delmas PD. Assessment of the role of 17beta-oestradiol in bone metabolism in men: does the assay technique matter? The MINOS study. Clin Endocrinol (Oxf) 2004, 61:447-457.
81. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003, 88:204-210. 10.1210/jc.2002-021036, 12519853.
82. Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int 2005, 16:1487-1494. 10.1007/s00198-005-1890-8, 15856361.
83. Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003, 88:3785-3793. 10.1210/jc.2002-021643, 12915670.
84. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009, 94:4785-4792. 10.1210/jc.2009-0739, 2795655, 19820017.
85. Hero M, Toiviainen-Salo S, Wickman S, Mäkitie O, Dunkel L. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010, 25:1536-1543. 10.1002/jbmr.56, 20200972.
86. Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity and body composition. Eur J Endocrinol 2006, 155:453-460. 10.1530/eje.1.02226, 16914600.
87. Hero M, Maury S, Luotoniemi E, Service E, Dunkel L. Cognitive effects of aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol 2010, 163:149-155. 10.1530/EJE-10-0040, 20421333.
88. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskind MA, Johnson M, Craft S. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005, 64:290-296. 10.1212/01.WNL.0000149639.25136.CA, 15668427.